BPC-157: What Preclinical Research Shows

For laboratory research use only. BPC-157 is not approved by the FDA and is not intended for human or animal administration. This article summarizes published preclinical literature and makes no claims about effects in humans.

BPC-157 is one of the most studied synthetic peptides in preclinical tissue research. It is a 15-amino-acid sequence (a pentadecapeptide) derived from a protective protein found in gastric juice, which is why the literature often calls it a “stable gastric pentadecapeptide.” This overview summarizes what animal and cell-culture studies have examined, how researchers model its activity, and what to look for when sourcing BPC-157 for a study.

What is BPC-157?

BPC stands for “Body Protection Compound.” The research sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of roughly 1,419 Da. Its notable property for laboratory work is stability: unlike many short peptides, it has been reported to remain intact in gastric conditions, which made it a convenient tool compound for gastrointestinal models and later for tendon, ligament and skin models.

Areas of preclinical research

Wound and soft-tissue models

Early work from the Zagreb group established BPC-157 as a subject of wound research in rodents (Seiwerth et al., 1997). A 2021 review in Frontiers in Pharmacology collected two decades of these animal studies across skin, muscle, tendon and gastrointestinal models (Seiwerth et al., 2021). Researchers should note that most of this literature comes from a small number of laboratories, and independent replication remains limited.

Angiogenesis and cell migration in vitro

Cell-culture studies have examined how BPC-157 may influence endothelial cell proliferation, migration and tube formation — standard in vitro readouts for angiogenesis. One study combined an alkali-burn model in rats with in vitro endothelial assays and reported increased migration and angiogenic markers (Huang et al., 2015).

Tendon fibroblast research

Tendon work is one of the more mechanistic branches of the literature. Researchers using rat tendon explants and fibroblast cultures reported effects on tendon outgrowth, cell survival and migration (Chang et al., 2011). A follow-up study examined growth hormone receptor expression in tendon fibroblasts exposed to BPC-157 (Chang et al., 2014), proposing one pathway through which the peptide may interact with growth signaling in vitro.

How BPC-157 is studied alongside TB-500

BPC-157 is frequently examined in parallel with TB-500 (a synthetic fragment related to thymosin beta-4) because both appear in tissue repair and cell migration literature but through different proposed mechanisms. Thymosin beta-4 research centers on actin binding and cell motility (Malinda et al., 1999), while BPC-157 research centers on angiogenic and growth-factor signaling. Laboratories comparing the two often use a BPC-157 + TB-500 blend alongside single-compound controls.

Limitations of the current evidence

• Most studies are in rodents or cell culture; controlled human data are lacking.
• A large share of publications originate from one research group.
• Study designs, concentrations and endpoints vary, which makes cross-study comparison difficult.

These gaps are why BPC-157 remains a research compound, and why consistent, well-characterized material matters for reproducible results.

Sourcing BPC-157 for research: what to check

• Purity by HPLC: look for a batch-specific chromatogram showing ≥99% main-peak area.
• Identity by mass spectrometry: the observed mass should match the theoretical ~1,419 Da.
• Batch-specific Certificate of Analysis: the COA lot number should match the vial. See our guide to understanding COA documentation.
• Storage: lyophilized peptide should be kept cold and dry; see why storage conditions matter.

BioRhex supplies research-grade BPC-157 manufactured in a GMP-compliant US facility, HPLC and mass spectrometry verified, with a batch COA in every order. Browse the full Recovery & Tissue Research category for related compounds.

References

1. Seiwerth S, Sikiric P, Grabarević Ž, et al. (1997). BPC 157’s effect on healing. Journal of Physiology-Paris, 91(3–5), 173–178. https://doi.org/10.1016/S0928-4257(97)89480-6
2. Huang T, Zhang K, Sun L, et al. (2015). Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Design, Development and Therapy, 9, 2485–2499. https://doi.org/10.2147/DDDT.S82030
3. Seiwerth S, Milavić M, Vukojević J, et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533
4. Chang CH, Tsai WC, Lin MS, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780. https://doi.org/10.1152/japplphysiol.00945.2010
5. Chang CH, Tsai WC, Hsu YH, Pang JHS. (2014). Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules, 19(11), 19066–19077. https://doi.org/10.3390/molecules191119066
6. Malinda KM, Sidhu GS, Mani H, et al. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 113(3), 364–368. https://doi.org/10.1046/j.1523-1747.1999.00708.x